ReCode Therapeutics

ReCode Therapeutics is at the forefront of revolutionizing genetic medicines through unparalleled delivery systems. The company’s innovative platform pioneers targeted delivery technologies that empower mRNA therapeutics and gene correction for previously untreatable genetic diseases, including primary ciliary dyskinesia and cystic fibrosis. ReCode's SELECTIVE ORGAN TARGETING (SORT) lipid nanoparticle (LNP) technology represents a breakthrough in the delivery of genetic therapies by allowing precise targeting beyond the liver, thus opening unprecedented possibilities for treating rare disorders.

The foundation of ReCode's pioneering approach is rooted in unconventional thinking and scientific bravery, as seen in the work of co-founder Professor Daniel J. Siegwart, Ph.D. With over 20 years of industry limitation in the understanding of lipid nanoparticles, ReCode emerged to change this landscape by advancing how genetic medicines can be delivered effectively. Engaging in partnerships and collaborations with esteemed academic institutions and organizations, ReCode is focused on growing its clinical pipeline of genetic medicines aimed at addressing critical health challenges faced by patients worldwide. Through continuous innovation, ReCode aims to reshape the future of genetic medicine and enhance the quality of life for individuals impacted by genetic diseases.